A new comprehensive review is shedding light on the expanding role of focal adhesion kinase (FAK) in cancer biology and its potential as a next-generation therapeutic target for solid tumors. The study brings together current evidence describing how FAK drives tumor progression, regulates the tumor microenvironment, and influences responses to modern cancer therapies.
FAK is a cytoplasmic non-receptor tyrosine kinase that integrates signals from integrins, growth factors, and other cellular receptors. By transmitting signals related to cell adhesion and extracellular matrix interactions, FAK regulates essential biological processes including cell migration, proliferation, survival, and metastasis. In many solid tumors, FAK is overexpressed or hyperactivated, and elevated FAK activity is strongly associated with tumor progression, lymph node metastasis, and poor clinical outcomes.
According to the review, FAK activation occurs through multiple mechanisms. The canonical pathway involves integrin-mediated signaling, where extracellular matrix interactions trigger autophosphorylation at key residues, leading to downstream activation of oncogenic signaling pathways such as PI3K/AKT and MAPK. However, the authors emphasize that non-integrin pathways also play crucial roles. Receptor tyrosine kinases, G-protein-coupled receptors, transmembrane proteins, and even non-coding RNAs can independently activate FAK, illustrating the complexity of the signaling network surrounding this molecule.
Beyond tumor cell–intrinsic effects, FAK has emerged as an important regulator of the tumor microenvironment. The review highlights evidence showing that FAK influences immune cell infiltration, fibrosis, angiogenesis, and stromal cell activity. These functions allow tumors to create immunosuppressive environments that weaken antitumor immune responses, making FAK a potential bridge between targeted therapy and immunotherapy approaches.
FAK signaling also contributes to several hallmarks of cancer. The authors summarize studies demonstrating that activated FAK promotes epithelial–mesenchymal transition, tumor invasion and metastasis, cancer stem cell maintenance, and resistance to chemotherapy or targeted therapies. Inhibition of FAK has been shown in preclinical studies to reduce metastatic potential and reverse drug resistance, suggesting broad translational potential.
Despite strong biological rationale, translating FAK inhibition into clinical success has been challenging. Several small-molecule FAK inhibitors have reached clinical trials, including defactinib and other ATP-competitive agents. While early results have shown acceptable safety and disease stabilization in some patient populations, monotherapy strategies have generally produced limited efficacy. Researchers increasingly believe that combination strategies represent the most promising path forward.
The review points to growing evidence that combining FAK inhibitors with chemotherapy, targeted therapy, radiotherapy, or immune checkpoint inhibitors may produce synergistic effects. In particular, FAK inhibition appears capable of reshaping the tumor microenvironment, increasing cytotoxic T cell infiltration, and enhancing responses to immunotherapy in certain tumor models. Early clinical studies combining FAK inhibitors with immunotherapy or targeted agents have shown encouraging signals, supporting continued investigation.
In addition to conventional kinase inhibitors, researchers are developing a new generation of FAK-targeting approaches. Emerging technologies include proteolysis-targeting chimeras (PROTACs) designed to degrade FAK protein entirely, inhibitors that disrupt protein-protein interactions, allosteric modulators, and natural compounds that interfere with FAK-driven signaling. These strategies aim to overcome resistance mechanisms and target both the enzymatic and scaffold functions of FAK, which may offer deeper therapeutic responses.
The authors conclude that FAK represents more than a single signaling molecule; it acts as a central organizer that links tumor cell behavior with the surrounding microenvironment. Future progress will likely depend on improved patient stratification, biomarker discovery, and integrative approaches that combine multi-omics technologies with advanced drug development.
As cancer therapy increasingly moves toward precision medicine and combination-based treatment models, the review suggests that targeting FAK could play a pivotal role in shaping next-generation therapeutic strategies for solid tumors.
Science Bulletin
Systematic review